Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12-year period that responded dramatically to treatment with infliximab. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed.
Rongioletti
F
F
Department of Dermatology, University of Genoa, Genoa, Italy.
Borenstein
M
M
Kirsner
Robert
R
Kerdel
Francisco
F
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D018570:Risk Assessment; D016879:Salvage Therapy; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000069285:Infliximab